Trials / Active Not Recruiting
Active Not RecruitingNCT05385471
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M, Both Alone and in Combination, in Healthy UK Adults
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M
Detailed description
Volunteers will be recruited into one of four groups (n=8+1 per group) at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford. Volunteers in groups 1, 2 and 4 will be followed up for a total of approximately 12 months. There will be 3 sentinel participants in each group (and for each successive vaccination), which will require an independent safety review prior to each successive vaccination. Group 3 is not a first-in-human group and so can be recruited at any time and participants will be followed up for a total of approximately 20 months from first vaccination. All volunteers will be given 10 µg R78C and/or 10 µg RH5.1 soluble protein in combination with 50 µg of Matrix-M via intramuscular (IM) injection in the deltoid region of the non-dominant arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Matrix M with R78C and/or RH5.1 | 50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints |
Timeline
- Start date
- 2023-01-13
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2022-05-23
- Last updated
- 2025-04-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05385471. Inclusion in this directory is not an endorsement.